ClinicalTrials.gg
TerminatedNCT05582395ODYSSEY-HCMUpdated Sep 18, 2026Results posted

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

A Phase 3 interventional study of Mavacamten and Placebo in Cardiomyopathy, Hypertrophic, sponsored by Bristol-Myers Squibb. Terminated at 224 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was terminated
Trial terminated because of lack of efficacy in the short term acute phase

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
580
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 4 open to participants now, 8 under way, 2 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
Largest of 22
580 · median 77
Started
2022
with 3 others
Phase 3
7 of 22
1 open now
Registered
13th of 22
by date
Lead sponsor
11 of 22
Bristol-Myers Squibb

Among the 22 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one has the largest enrollment, is one of 4 that started in 2022, is one of 7 in phase 3, and was the 13th registered.

Cardiomyopathy, Hypertrophic

364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 117 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

4 of the 22 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

03

Conditions studied

  • Cardiomyopathy, Hypertrophic

Keywords

  • Mavacamten
  • non-obstructive HCM
  • non-obstructive hypertrophic cardiomyopathy (nHCM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HCM consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines: unexplained left-ventricular hypertrophy with non-dilated ventricular chambers in the absence of other cardiac or systemic disease which can produce the required magnitude of hypertrophy of a maximal left ventricular (LV) wall thickness ≥ 15 millimeters (mm) (or ≥ 13 mm with positive family history of hypertrophic cardiomyopathy [HCM]) as determined by core laboratory interpretation.
  • Peak left ventricular outflow tract (LVOT) pressure gradient \< 30 millimeters mercury (mm Hg) at rest and \< 50 mm Hg with provocation (Valsalva maneuver and stress echocardiography).
  • (NYHA) Class II or III.

Exclusion criteria

Exclusion Criteria

  • Known infiltrative or storage disorder causing cardiac hypertrophy that mimics non-obstructive hypertrophic cardiomyopathy (nHCM) such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy.
  • History of unexplained syncope within 6 months prior to screening.
  • History of sustained ventricular tachyarrhythmia (> 30 seconds) within 6 months prior to screening.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
580 participants (actual)

Study arms

  • Experimental
    Mavacamten

    Drug: Mavacamten

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986427, MYK-461

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in KCCQ-23 CSS at Week 48

    The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

    Time frame: From First dose to week 48

  2. Change From Baseline in pVO2 at Week 48

    Clinically meaningful mean change from baseline(1.4ml/kg/min) of pVO2 at Week 48.

    Time frame: From First dose to week 48

Secondary outcomes

  1. Change From Baseline in VE/VCO2 Slope at Week 48

    VE/VCO₂ slope was assessed using cardiopulmonary exercise testing (CPET). The slope was calculated as the linear regression of minute ventilation (VE) against carbon dioxide production (VCO₂). A decrease in VE/VCO₂ slope reflects improved ventilatory efficiency.

    Time frame: From First dose to week 48

  2. Mean Change From Baseline in NT-proBNP to Week 48

    Blood samples were collected for assessing the concentration of NT-proBNP. Baseline is defined as last non-missing measurement prior to the first dose.

    Time frame: From First dose to week 48

  3. Percentage of Participants With at Least 1 Class of NYHA Improvement From Baseline at Week 48

    Participants with \\\>= 1 NYHA function class improvement. The NYHA Functional Classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

    Time frame: From First dose to week 48

  4. Mean Change From Baseline in HCMSQ SoB Domain Score at Week 48

    The HCMSQ is a self- administered, 9-item questionnaire that assesses the core symptoms of HCM (shortness of breath, tiredness/fatigue, heart palpitations, chest pain, dizziness, and syncope). At each visit, a 7-day period will be defined, ending on the last day with a non-missing HCMSQ score prior to the actual clinic visit (or first dose date if baseline). If the participant completes the HCMSQ for 4 or more days within this period, the weekly average HCMSQ score will be calculated. If fewer than 4 days are completed, other 7-day periods will be considered. For baseline, any 7-day period with at least 4 days of HCMSQ prior to the first dose or randomization date (if first dose date is missing) will be used. Each domain of the SoB scale is scored 1 to 6. The scores are added together to give a total score. Lower scores indicating low to no shortness of breath, higher scores indicating frequent episodes of shortness of breath. the lower the score the better.

    Time frame: From First dose to week 48

07

Results

Posted Aug 20, 2026

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneTreatment 1Treatment 2
Started289291
Completed258274
Not completed3117
Withdrew: Lost to follow-up01
Withdrew: Non-compliance with study drug01
Withdrew: Physician decision30
Withdrew: Participant request to discontinue46
Withdrew: Withdrawal by subject21
Withdrew: Adverse event125
Withdrew: Lvef permanent discontinuation criteria met70
Withdrew: Other reasons33
Long Term Extension Period
Participant flow — Long Term Extension Period
MilestoneTreatment 1Treatment 2
Started289291
Completed00
Not completed289291
Withdrew: Lost to follow-up01
Withdrew: Non-compliance with study drug01
Withdrew: Physician decision41
Withdrew: Study closed out early due to sponsor251259
Withdrew: Participant request to discontinue treatment412
Withdrew: Withdrawal by subject33
Withdrew: Adverse event158
Withdrew: Lvef permanent discontinuation criteria met71
Withdrew: Other reasons55

Outcome measures

SecondaryChange From Baseline in VE/VCO2 Slope at Week 48

VE/VCO₂ slope was assessed using cardiopulmonary exercise testing (CPET). The slope was calculated as the linear regression of minute ventilation (VE) against carbon dioxide production (VCO₂). A decrease in VE/VCO₂ slope reflects improved ventilatory efficiency.

Time frame:
From First dose to week 48
Reported as:
Least squares mean · ratio
Change From Baseline in VE/VCO2 Slope at Week 48
ratioTreatment 1Treatment 2
Change From Baseline in VE/VCO2 Slope at Week 48-0.64 ± 0.6080.16 ± 0.603
Statistical analysis
  • Treatment 1 vs Treatment 2 · ANCOVA · Lsm diff: -0.81 · 95% CI -2.21 to 0.60ANCOVA with treatment and baseline, adjusted for IRT strata: NYHA class, exercise type, and baseline beta-blocker use.
SecondaryMean Change From Baseline in NT-proBNP to Week 48

Blood samples were collected for assessing the concentration of NT-proBNP. Baseline is defined as last non-missing measurement prior to the first dose.

Time frame:
From First dose to week 48
Reported as:
Geometric mean · ng/L
Mean Change From Baseline in NT-proBNP to Week 48
ng/LTreatment 1Treatment 2
Mean Change From Baseline in NT-proBNP to Week 480.42 ± 5.8421.02 ± 5.655
Statistical analysis
  • Treatment 1 vs Treatment 2 · ANCOVA · Geometric mean: 0.41 · 95% CI 0.36 to 0.47ANCOVA with treatment and baseline, adjusted for IRT strata: NYHA class, exercise type, and baseline beta-blocker use.
SecondaryPercentage of Participants With at Least 1 Class of NYHA Improvement From Baseline at Week 48

Participants with \\\>= 1 NYHA function class improvement. The NYHA Functional Classification of heart failure assigns participants to 1 of 4 categories based on the participant's symptoms. Class 1: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). Class 2: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). Class 3: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. Class 4: Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

Time frame:
From First dose to week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least 1 Class of NYHA Improvement From Baseline at Week 48
Percentage of ParticipantsTreatment 1Treatment 2
Percentage of Participants With at Least 1 Class of NYHA Improvement From Baseline at Week 4836.33 (30.79 to 41.88)31.62 (26.27 to 36.96)
Statistical analysis
  • Treatment 1 vs Treatment 2 · Miettinen and Nurminen method · Risk difference (rd): 5.01 · 95% CI -2.25 to 12.23Stratified by IRT factors: NYHA class II/III, exercise type (treadmill/bike), and baseline beta-blocker use.
SecondaryMean Change From Baseline in HCMSQ SoB Domain Score at Week 48

The HCMSQ is a self- administered, 9-item questionnaire that assesses the core symptoms of HCM (shortness of breath, tiredness/fatigue, heart palpitations, chest pain, dizziness, and syncope). At each visit, a 7-day period will be defined, ending on the last day with a non-missing HCMSQ score prior to the actual clinic visit (or first dose date if baseline). If the participant completes the HCMSQ for 4 or more days within this period, the weekly average HCMSQ score will be calculated. If fewer than 4 days are completed, other 7-day periods will be considered. For baseline, any 7-day period with at least 4 days of HCMSQ prior to the first dose or randomization date (if first dose date is missing) will be used. Each domain of the SoB scale is scored 1 to 6. The scores are added together to give a total score. Lower scores indicating low to no shortness of breath, higher scores indicating frequent episodes of shortness of breath. the lower the score the better.

Time frame:
From First dose to week 48
Reported as:
Least squares mean · Score on a Scale
Mean Change From Baseline in HCMSQ SoB Domain Score at Week 48
Score on a ScaleTreatment 1Treatment 2
Mean Change From Baseline in HCMSQ SoB Domain Score at Week 48-1.76 ± 0.208-1.06 ± 0.207
Statistical analysis
  • Treatment 1 vs Treatment 2 · ANCOVA · Lsm diff: -0.70 · 95% CI -1.18 to -0.22ANCOVA with treatment and baseline, adjusted for IRT strata: NYHA class, exercise type, and baseline beta-blocker use.
PrimaryChange From Baseline in KCCQ-23 CSS at Week 48

The KCCQ-23 is a 23-item, self-administered questionnaire that measures the impact of a participant's cardiovascular disease or its treatment on 6 distinct domains using a 2-week recall period: symptoms/signs, physical limitation, quality of life (QoL), social limitations, self-efficacy, and symptom stability. The KCCQ 23 Clinical Summary Score (CSS) is derived from the Total Symptom Score (TSS) and the Physical Limitations (PL) score of the KCCQ 23. The CSS, TSS, and the PL score range from 0 to 100 with higher scores representing less severe symptoms and/or physical limitations. The CSS is a mean of the TSS and the PL score. Baseline is defined as the last non-missing assessment prior to the first dose of the study treatment if both the time of the measurement and the time of first dose are available otherwise it is the last non-missing assessment on or prior to the first dose of the study treatment.

Time frame:
From First dose to week 48
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in KCCQ-23 CSS at Week 48
Score on a ScaleTreatment 1Treatment 2
Change From Baseline in KCCQ-23 CSS at Week 4813.13 ± 1.22210.38 ± 1.214
Statistical analysis
  • Treatment 1 vs Treatment 2 · ANCOVA · p = 0.056 (ANCOVA with treatment and baseline, adjusted for IRT strata: NYHA class, exercise type, and baseline beta-blocker use.) · Least square mean difference: 2.74 · 95% CI -0.08 to 5.56
PrimaryChange From Baseline in pVO2 at Week 48

Clinically meaningful mean change from baseline(1.4ml/kg/min) of pVO2 at Week 48.

Time frame:
From First dose to week 48
Reported as:
Least squares mean · mL/kg/min
Change From Baseline in pVO2 at Week 48
mL/kg/minTreatment 1Treatment 2
Change From Baseline in pVO2 at Week 480.52 ± 0.2200.05 ± 0.216
Statistical analysis
  • Treatment 1 vs Treatment 2 · ANCOVA · p = 0.066 · Least square mean: 0.47 · 95% CI -0.03 to 0.98ANCOVA with treatment and baseline, adjusted for IRT strata: NYHA class, exercise type, and baseline beta-blocker use.

Adverse events

Collected over Adverse Events and Serious Adverse Events: (From first dose to last dose + 120 days): Approximately 173 Weeks All-Cause mortality (From randomization to end of study): Approximately 178 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MAVACAMTEN1/34 (2.9%)18/34 (52.9%)26/34 (76.5%)
PLACEBO1/19 (5.3%)8/19 (42.1%)17/19 (89.5%)
MAVACAMTEN/MAVACAMTEN1/254 (0.4%)63/254 (24.8%)201/254 (79.1%)
PLACEBO/MAVACAMTEN2/271 (0.7%)55/271 (20.3%)192/271 (70.8%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventMAVACAMTENPLACEBOMAVACAMTEN/MAVACAMTENPLACEBO/MAVACAMTEN
Atrial fibrillationCardiac disorders7/342/197/25410/271
Cardiac failureCardiac disorders6/341/196/2545/271
Cardiac failure congestiveCardiac disorders3/340/192/2540/271
Angina pectorisCardiac disorders0/341/193/2541/271
Angina unstableCardiac disorders0/341/190/2540/271
Conduction disorderCardiac disorders0/341/190/2540/271
VomitingGastrointestinal disorders0/341/190/2540/271
DeathGeneral disorders0/341/190/2541/271
Non-cardiac chest painGeneral disorders0/341/191/2543/271
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/341/190/2540/271
Most frequent other events
Showing 10 of 63
Most frequent other events
EventMAVACAMTENPLACEBOMAVACAMTEN/MAVACAMTENPLACEBO/MAVACAMTEN
DyspnoeaRespiratory, thoracic and mediastinal disorders9/343/1946/25441/271
PalpitationsCardiac disorders2/345/1938/25428/271
Cardiac failureCardiac disorders7/340/1915/25415/271
FatigueGeneral disorders4/340/1946/25433/271
DizzinessNervous system disorders3/343/1938/25434/271
Atrial fibrillationCardiac disorders5/342/1930/25425/271
NasopharyngitisInfections and infestations2/342/1936/25431/271
HeadacheNervous system disorders1/342/1924/25421/271
COVID-19Infections and infestations2/340/1925/25424/271
Atrial flutterCardiac disorders3/340/194/2546/271

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Treatment 1Treatment 2Total
Mean56.4 ± 14.7155.7 ± 14.3956.0 ± 14.54
Sex: Female, Male
Sex: Female, Male(Participants)Treatment 1Treatment 2Total
Female141125266
Male148166314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment 1Treatment 2Total
Hispanic or Latino404282
Not Hispanic or Latino215222437
Unknown or Not Reported342761
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment 1Treatment 2Total
American Indian or Alaska Native000
Asian513990
Native Hawaiian or Other Pacific Islander000
Black or African American111425
White195205400
More than one race000
Unknown or Not Reported323365
08

Study locations

224 sites
  • Local Institution - 0082
    Birmingham, Alabama 35233-1900, United States
  • Local Institution - 0458
    Phoenix, Arizona 85054, United States
  • Local Institution - 0409
    La Jolla, California 92037-1337, United States
  • Local Institution - 0010
    Los Angeles, California 90048-3311, United States
  • Local Institution - 0406
    San Francisco, California 94143-2204, United States
  • Local Institution - 0079
    Stanford, California 94305-2200, United States
  • Local Institution - 0468
    Gainesville, Florida 32608-1134, United States
  • Local Institution - 0281
    Tampa, Florida 33606-3603, United States
  • Local Institution - 0092
    Atlanta, Georgia 30322, United States
  • Local Institution - 0424
    Indianapolis, Indiana 46202-1243, United States
  • Local Institution - 0070
    Iowa City, Iowa 52242-1009, United States
  • Local Institution - 0410
    Kansas City, Kansas 66160-8500, United States
  • Local Institution - 0484
    Louisville, Kentucky 40217-1363, United States
  • Local Institution - 0127
    Baltimore, Maryland 21287, United States
  • Local Institution - 0479
    Boston, Massachusetts 02114, United States
  • Local Institution - 0500
    Boston, Massachusetts 02118-2908, United States
  • Local Institution - 0464
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0064
    Detroit, Michigan 48202-2608, United States
  • Local Institution - 0455
    Grand Rapids, Michigan 49525, United States
  • Local Institution - 0431
    Rochester, Minnesota 55905, United States
  • Local Institution - 0461
    St Louis, Missouri 63110, United States
  • Local Institution - 0435
    Omaha, Nebraska 68198-2265, United States
  • Local Institution - 0490
    Morristown, New Jersey 07962, United States
  • Local Institution - 0449
    Manhasset, New York 11030-3816, United States
  • Local Institution - 0486
    New York, New York 10019-1147, United States
  • Local Institution - 0007
    Stony Brook, New York 11790-3407, United States
  • Local Institution - 0426
    Valhalla, New York 10595, United States
  • Local Institution - 0094
    Charlotte, North Carolina 28204-2826, United States
  • Local Institution - 0065
    Durham, North Carolina 27710, United States
  • Local Institution - 0083
    Cleveland, Ohio 44195, United States
  • Local Institution - 0047
    Hershey, Pennsylvania 17033, United States
  • Local Institution - 0444
    Lancaster, Pennsylvania 17602-2250, United States
  • Local Institution - 0263
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0081
    Pittsburgh, Pennsylvania 15213-2536, United States
  • Local Institution - 0207
    Germantown, Tennessee 38138-1727, United States
  • Local Institution - 0089
    Dallas, Texas 75246, United States
  • Local Institution - 0365
    Dallas, Texas 75390, United States
  • Local Institution - 0492
    Plano, Texas 75093, United States
  • Local Institution - 0402
    Salt Lake City, Utah 84132-0001, United States
  • Local Institution - 0478
    Charlottesville, Virginia 22908-0001, United States
  • Local Institution - 0095
    Richmond, Virginia 23298-5024, United States
  • Local Institution - 0063
    Concord, New South Wales 2139, Australia
  • Local Institution - 0085
    Darlinghurst, New South Wales 2010, Australia
  • Local Institution - 0369
    Sydney, New South Wales 2170, Australia
  • Local Institution - 0080
    Chermside, Queensland 4032, Australia
  • Local Institution - 0078
    Milton, Queensland 4064, Australia
  • Local Institution - 0050
    Bedford Park, South Australia 5042, Australia
  • Local Institution - 0076
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0090
    Innsbruck, Tyrol 6020, Austria
  • Local Institution - 0075
    Linz, Upper Austria 4020, Austria
  • Local Institution - 0069
    Braunau am Inn, Upper Austria (Oberösterreich) 5280, Austria
  • Local Institution - 0062
    Graz, 8036, Austria
  • Local Institution - 0429
    Vienna, 1090, Austria
  • Local Institution - 0462
    Edegem, Antwerpen 2650, Belgium
  • Local Institution - 0034
    Anderlecht, Brussels Capital 1070, Belgium
  • Local Institution - 0476
    Genk, Limburg 3600, Belgium
  • Local Institution - 0319
    Leuven, Vlaams Brabant 3000, Belgium
  • Local Institution - 0413
    Salvador, Estado de Bahia 40170-130, Brazil
  • Local Institution - 0438
    Brasília, Federal District 70710-140, Brazil
  • Local Institution - 0488
    Belo Horizonte, Minas Gerais 30220-140, Brazil
  • Local Institution - 0447
    Porto Alegre, Rio Grande do Sul 90560-030, Brazil
  • Local Institution - 0450
    Porto Alegre, Rio Grande do Sul 90620-001, Brazil
  • Local Institution - 0430
    Bragança Paulista, São Paulo 12916-542, Brazil
  • Local Institution - 0422
    Ribeirão Preto, São Paulo 14026-900, Brazil
  • Local Institution - 0412
    São Paulo, São Paulo 05403-000, Brazil
  • Local Institution - 0446
    Rio de Janeiro, 20551-030, Brazil
  • Local Institution - 0451
    Rio de Janeiro, 22061-080, Brazil
  • Local Institution - 0418
    São Paulo, 04012-180, Brazil
  • Local Institution - 0381
    Calgary, Alberta T2N 1N4, Canada
  • Local Institution - 0467
    Vancouver, British Columbia V6E 1M7, Canada
  • Local Institution - 0414
    Hamilton, Ontario L8L 2X2, Canada
  • Local Institution - 0411
    London, Ontario N6A 5A5, Canada
  • Local Institution - 0093
    Québec, Quebec G1V 4G5, Canada
  • Local Institution - 0535
    Beijing, Beijing Municipality 100083, China
  • Local Institution - 0534
    Beijing, Beijing Municipality 100730, China
  • Local Institution - 0503
    Chongqing, Chongqing Municipality 400016, China
  • Local Institution - 0541
    Chongqing, Chongqing Municipality 400016, China
  • Local Institution - 0539
    Guangzhou, Guangdong 510120, China
  • Local Institution - 0543
    Guangzhou, Guangdong 510515, China
  • Local Institution - 0549
    Zhengzhou, Henan 450003, China
  • Local Institution - 0542
    Wuhan, Hubei 430060, China
  • Local Institution - 0548
    Changsha, Hunan 410011, China
  • Local Institution - 0545
    Suzhou, Jiangsu 215006, China
  • Local Institution - 0550
    Nanchang, Jiangxi 330008, China
  • Local Institution - 0544
    Changchun, Jilin 130041, China
  • Local Institution - 0540
    Dalian, Liaoning 116011, China
  • Local Institution - 0501
    Shenyang, Liaoning 110016, China
  • Local Institution - 0538
    Shenyang, Liaoning 110016, China
  • Local Institution - 0547
    Xi'an, Shan1xi 710061, China
  • Local Institution - 0546
    Jinan, Shandong 250021, China
  • Local Institution - 0537
    Shanghai, Shanghai Municipality 200127, China
  • Local Institution - 0533
    Chengdu, Sichuan 610000, China
  • Local Institution - 0552
    Chengdu, Sichuan 610015, China
  • Local Institution - 0536
    Wenzhou, Zhejiang 325000, China
  • Local Institution - 0502
    Beijing, 100730, China
  • Local Institution - 0553
    Beijing, 102218, China
  • Local Institution - 0086
    Broumov, Hradec Králové Region 550 01, Czechia
  • Local Institution - 0052
    Prague, Praha, Hlavní Mesto 128 21, Czechia
  • Local Institution - 0033
    Prague, Praha, Hlavní Mesto 140 21, Czechia
  • Local Institution - 0188
    Brno, 656 91, Czechia

Showing the first 100 of 224 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Desai MY, Owens AT, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Elliott P, Fernandes F, Verheyen N, Maier L, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Jaber W, Mitchell L, Myers J, Rano T, Gong Z, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Nissen SE; ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025 Sep 11;393(10):961-972. doi: 10.1056/NEJMoa2505927. Epub 2025 Aug 30. PubMed 40888717 ↗
  • Desai MY, Olivotto I, Abraham T, Nissen SE, Garcia-Pavia P, Lopes RD, Elliott PM, Fernandes F, de Barros Correia E, Barriales-Villa R, Zorio E, Arad M, Shin SH, Verheyen N, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Suryawanshi B, Wang Z, Florea V, Aronson R, Owens AT; ODYSSEY-HCM Investigators. Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial. J Am Coll Cardiol. 2025 Dec 16;86(24):2418-2433. doi: 10.1016/j.jacc.2025.08.017. Epub 2025 Aug 27. PubMed 40864018 ↗
  • Sikand N, Stendahl J, Sen S, Lampert R, Day S. Current management of hypertrophic cardiomyopathy. BMJ. 2025 May 27;389:e077274. doi: 10.1136/bmj-2023-077274. PubMed 40425241 ↗
  • Desai MY, Nissen SE, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, Verheyen N, Wever-Pinzon O, Wolski K, Jaber W, Mitchell L, Davey D, Myers J, Rano T, Bhatia V, Zhong Y, Carter-Bonanza S, Florea V, Aronson R, Owens AT; ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM. JACC Heart Fail. 2025 Feb;13(2):358-370. doi: 10.1016/j.jchf.2024.11.013. PubMed 39909647 ↗
  • O'Malley PA. Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy. Clin Nurse Spec. 2024 May-Jun 01;38(3):119-121. doi: 10.1097/NUR.0000000000000821. No abstract available. PubMed 38625800 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Mar 2025, 26 months.

Results were first posted in Aug 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2022
First posted
Oct 17, 2022
StartActual
Dec 14, 2022
Primary completionActual
Mar 6, 2025
CompletionActual
Oct 20, 2025
Results first posted
Aug 20, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05582395
Responsible party
Sponsor
First posted
Oct 17, 2022
Start date
Dec 14, 2022
Primary completion
Mar 6, 2025
Completion
Oct 20, 2025
Results posted
Aug 20, 2026
Last update
Sep 18, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion